Eesti - eesti - Ravimiamet

bavarian nordic a/s - puukentsefaliidi koguviirus, inaktiveeritud - süstesuspensioon süstlis - 0,75mcg 0.25ml 0.25ml 1tk; 0,75mcg 0.25ml 0.25ml 10tk

Eesti - eesti - Ravimiamet

pfizer europe ma eeig - puukentsefaliidi koguviirus, inaktiveeritud - süstesuspensioon süstlis - 1annus 0.25ml 0.25ml 1tk

Eesti - eesti - Ravimiamet

bavarian nordic a/s - puukentsefaliidi koguviirus, inaktiveeritud - süstesuspensioon süstlis - 1,5mcg 0.5ml 0.5ml 10tk; 1,5mcg 0.5ml 0.5ml 1tk; 1,5mcg 0.5ml 0.5ml 20tk

Eesti - eesti - Ravimiamet

pfizer europe ma eeig - puukentsefaliidi koguviirus, inaktiveeritud - süstesuspensioon süstlis - 1annus 0.5ml 0.5ml 1tk; 1annus 0.5ml 0.5ml 10tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

valneva austria gmbh - jaapani-entsefaliidi viirus, inaktiveeritud (veresoones kasvanud nõrgestatud tüvi sa14-14-2) - encephalitis, japanese; immunization - vaktsiinid - ixiaro on näidustatud jaapani entsefaliidi vastu aktiivseks immuniseerimiseks täiskasvanutel, noorukitel, lastel ja imikutel, kelle vanus on vähemalt kaks kuud. ixiaro tuleks kaaluda kasutamiseks ohustatud isikud kokkupuute kaudu reisida või selle käigus oma elukutse.

Eesti - eesti - Ravimiamet

accord healthcare b.v. - atsikloviir - infusioonilahuse kontsentraat - 25mg 1ml 10ml 5tk; 25mg 1ml 40ml 5tk; 25mg 1ml 20ml 1tk; 25mg 1ml 40ml 10tk

Eesti - eesti - Ravimiamet

valneva austria gmbh - jaapani entsefaliidi koguviirus, inaktiveeritud - süstesuspensioon - 1annus 0.5ml 0.5ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - dermatiidi ained, välja arvatud kortikosteroidid - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.